Introduction
============

Use of radiotherapy with or without chemotherapy as primary treatment for cancer of the head and neck has increased over the past decades. Although the primary goal of treatment is to cure, a perceived additional benefit is the preservation of the organs of the head and neck. Thus, swallowing function after treatment is of major interest.[@JR0170or-1] However, the current literature indicates that, despite the anatomical preservation of the structures, swallowing function is not maintained at normal levels after treatment.[@JR0170or-2] [@JR0170or-3] [@JR0170or-4] Some alternative feeding route can be necessary due to dysphagia during or after the oncological treatment, which can impair the patient\'s quality of life (QOL).[@JR0170or-5] [@JR0170or-6] [@JR0170or-7]

Although many modalities could demonstrate organic dysfunction in swallowing, the patient\'s subjective self-perception seems the most significant outcome measure. A questionnaire for measuring a patient\'s perception of dysphagia and its effect on QOL was developed.[@JR0170or-5] [@JR0170or-6] [@JR0170or-7] This tool, known as the Quality of Life in Swallowing Disorders (SWAL-QOL)[@JR0170or-8] [@JR0170or-9] [@JR0170or-10] questionnaire, is validated, reliable, and reproducible for assessing the perception of dysphagia and has been validated in Brazilian Portuguese.[@BR0170or-11] Recently, the psychometric and clinical validity of the SWAL-QOL questionnaire was tested in patients with oral and oropharyngeal cancer and was found to be reliable, clinically feasible, and useful for evaluating swallowing problems. A difference of 12 points or more in score was considered clinically and statistically relevant in comparing groups of patients.[@JR0170or-12]

The aim of this study is to evaluate swallowing-related QOL in patients who underwent radiotherapy or chemoradiotherapy for treatment of head and neck tumors.

Methods
=======

This cross-sectional study consisted of 110 previously untreated patients from 21 to 87 years old (median, 61; 77.3% men and 22.7% women) who underwent radiotherapy or concomitant chemoradiotherapy for the treatment of head and neck squamous cell carcinoma. The protocol was approved by the research board, and the patients gave their consent for participation in this study. They were prospectively enrolled in the study from 6 to 12 months after the treatment ended. All patients were evaluated between May and August 2012 at the Service of Radiotherapy of the institution in which treatment was performed. All patients completed the study. Their data are presented in [Table 1](#TB0170or-1){ref-type="table"}.

###### Patient characteristics (*n* = 110)

  -----------------------------------------------------------------------------
  Variable               Category                                 *n* (%)
  ---------------------- ---------------------------------------- -------------
  Age (y)                Minimum--maximum\                        21--87\
                         25th percentile\                         56.0\
                         50th percentile (median)\                62.0\
                         75th percentile                          69.0

  Sex                    Female\                                  25 (22.70)\
                         Male                                     85 (77.30)

  Tumor site             Oral cavity\                             8 (7.30)\
                         Oropharynx\                              33 (30.0)\
                         Nasopharynx\                             9 (8.20)\
                         Larynx\                                  24 (21.80)\
                         Hypopharynx\                             10 (9.10)\
                         Unknown primary                          26 (23.60)

  T                      T0\                                      2 (1.80)\
                         T1\                                      27 (24.50)\
                         T2\                                      24 (21.80)\
                         T3\                                      28 (25.50)\
                         T4                                       29 (26.40)

  N                      N0\                                      63 (57.30)\
                         N1\                                      9 (8.20)\
                         N2a\                                     16 (14.50)\
                         N2b\                                     10 (9.10)\
                         N2c\                                     7 (6.40)\
                         N3                                       5 (4.50)

  Treatment modalities   Exclusively conventional radiotherapy\   28 (25.50)\
                         Chemoradiation                           82 (74.50)

  Nasogastric tube       No\                                      77 (70)\
                         During radiotherapy\                     9 (8.20)\
                         During and after radiotherapy\           16 (14.50)\
                         In use                                   8 (7.30)

  Tracheotomy            No\                                      85 (77.30)\
                         Definitive\                              8 (7.30)\
                         During radiotherapy\                     13 (11.80)\
                         Under temporary use                      4 (3.60)

  Keep smoking           No\                                      66 (60)\
                         Yes                                      44 (40)

  Keep drinking          No\                                      80 (72.70)\
                         Yes                                      30 (27.30)
  -----------------------------------------------------------------------------

The patients were asked to fill out the SWAL-QOL questionnaire previously validated in Brazilian Portuguese.[@BR0170or-11] It is a 44-item tool for assessing swallowing-related WOL, using 11 domains, including burden, desire, eating duration, symptoms frequency, food selection, communication, fear, mental health, sleep, social, and fatigue. Scores were calculated from each SWAL-QOL domain on a scale from 0 to 100, with a score of 100 representing the most favorable state.

The questionnaires were filled out once in a cross-sectional analysis by the patient alone or with the help of a relative or an interviewer if the patient was illiterate. Epidemiologic and clinicopathologic details were obtained from the charts.

Central trend and variability measurements were used to describe the numerical variables and the frequency distributions for categorical variables. To investigate associations between numerical variables (measurements) in groups with two categories, the nonparametric Mann-Whitney *U* test was applied; with three or more categories, the nonparametric Kruskal-Wallis test was used. When statistically significant differences were identified, the significance value was adjusted by means of Bonferroni correction. A significance level of 5% was used for all statistical tests, unless adjusted through Bonferroni correction, in which cases new significance values are presented. The IBM-SPSS statistical computer software (IBM-SPSS Statistics GradPack, Armonk, USA), version 21.0, was used to perform the statistical analysis.

Results
=======

The SWAL-QOL questionnaire indicated low median levels, generally with worse scores for desire, mental health, burden, and eating duration domains ([Table 2](#TB0170or-2){ref-type="table"}).

###### Quality of life in swallowing disorders (SWAL-QOL)

  Variable            *n*   min.--max.   25th percentile   50th percentile   75th percentile
  ------------------- ----- ------------ ----------------- ----------------- -----------------
  Burden              110   0--100       25                50                100
  Desire              110   0--100       16                41                66
  Eating duration     110   0--100       25                25                75
  Symptom frequency   110   3.5--100     44                60                82
  Food selection      110   0--100       25                75                100
  Communication       110   0--100       25                75                100
  Fear                110   6.2--100     37                75                93
  Mental health       110   0--100       20                60                100
  Social              110   0--100       38                75                100
  Sleep               110   0--100       50                100               100
  Fatigue             110   0--100       41                75                100

Abbreviations: max., maximum; min., minimum; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

The association between sex and the SWAL-QOL questionnaire was verified and the scores showed higher QOL impact among men in almost all domains, including eating duration (*p* = 0.003), mental health (*p* = 0.006), and symptom frequency (*p* = 0.022). Other domains also presented differences of more than 12 points but lacked statistical significance (desire, communication, fear, and sleep; [Table 3](#TB0170or-3){ref-type="table"}).

###### Association between SWAL-QOL and sex

  Variable            Sex      *n*         min.--max.   25th percentile   50th percentile   75th percentile   *p*
  ------------------- -------- ----------- ------------ ----------------- ----------------- ----------------- --------------------------------------------
  Burden              Female   25          0--100       50                62                100               0.038[a](#FN0170or-4){ref-type="table-fn"}
  Male                85       0--100      25           50                93.75                               
  Total               110      0--100      25           50                100                                 
  Desire              Female   25          16.60--100   29                41                75                0.120
  Male                85       0--100      16           33                66                                  
  Total               110      0--100      16           41                66                                  
  Eating duration     Female   25          25--100      25                50                100               0.003[a](#FN0170or-4){ref-type="table-fn"}
  Male                85       0--100      25           50                50                                  
  Total               110      0--100      25           25                75                                  
  Symptom frequency   Female   25          26.70--100   53                76                83                0.022[a](#FN0170or-4){ref-type="table-fn"}
  Male                85       3.50--100   39           57                78                                  
  Total               110      3.50--100   44           60                82                                  
  Food selection      Female   25          25--100      25                75                100               0.287
  Male                85       0--100      25           75                100                                 
  Total               110      0--100      25           75                100                                 
  Communication       Female   25          0--100       50                75                100               0.204
  Male                85       0--100      25           75                100                                 
  Total               110      0--100      25           75                100                                 
  Fear                Female   25          25--100      46                81                100               0.111
  Male                85       6.20--100   34           75                87                                  
  Total               110      6.20--100   37           75                93                                  
  Mental health       Female   25          10--100      55                90                100               0.006[a](#FN0170or-4){ref-type="table-fn"}
  Male                85       0--100      12           50                100                                 
  Total               110      0--100      20           60                100                                 
  Social              Female   25          25--100      70                85                100               0.034[a](#FN0170or-4){ref-type="table-fn"}
  Male                85       0--100      35           70                100                                 
  Total               110      0--100      38           75                100                                 
  Sleep               Female   25          0--100       87                100               100               0.051
  Male                85       0--100      50           100               100                                 
  Total               110      0--100      50           100               100                                 
  Fatigue             Female   25          25--100      70                83                100               0.043[a](#FN0170or-4){ref-type="table-fn"}
  Male                85       0--100      33           75                100                                 
  Total               110      0--100      41           75                100                                 

Abbreviations: max., maximum; min., minimum; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: *p* value according to Mann-Whitney test.

*p* \< 0.05.

The primary tumor site was significantly correlated between oral cavity tumors and the fatigue domain (*p* = 0.041). There was a difference of more than 12 points in the communication domain for the larynx in comparison with other sites, which was not statistically significant.

Patients with advanced primary tumors (T4) had the worst results for the food selection (*p* = 0.037), communication (*p* = 0.022), and social (*p* = 0.021) domains. There were more than 12-point differences in scores for the burden, desire, eating duration, and mental health domains, suggesting that those patients had a worse QOL. On the other hand, the association between the regional stage (N) and the SWAL-QOL did not present a statistically significant correlation in the questionnaire domains.

A total of 82 of the 110 patients underwent chemotherapy concomitant to the radiotherapy. The result in the burden domain was worse in this group (*p* = 0.020) than in the group of exclusive radiotherapy. The scores presented a difference for the communication (50 × 25) and fatigue (27.08 × 50) domains but lacked statistical significance.

The presence of a nasogastric tube impacted on almost all domains, mainly eating duration (*p* \< 0.001), symptom frequency (*p* \< 0.001), food selection (*p* \< 0.001), mental health (*p* \< 0.001), and social (*p* \< 0.001; [Table 4](#TB0170or-4){ref-type="table"}). Bonferroni correction showed differences in the eating duration, frequency of symptoms, food selection, and mental health domains. Furthermore, the use of nasogastric tube during and after radiotherapy also interfered with some QOL aspects ([Table 5](#TB0170or-5){ref-type="table"}).

###### Association between SWAL-QOL and the presence of nasogastric tube

  Variable            Nasogastric tube   *n*            min.--max.    25th percentile   50th percentile   75th percentile                                 *p*
  ------------------- ------------------ -------------- ------------- ----------------- ----------------- ----------------------------------------------- -----------------------------------------------
  Burden              No                 77             0--100        25                50                100                                             0.032[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  0--100         0             50                62                                                                
  During/after RT     16                 12--100        25            37                68                                                                
                      In use             8              0--75         0                 25                34                                              
                      Total              110            0--100        25                50                100                                             
  Desire              No                 77             0--100        25                41                75                                              0.093
  During RT           9                  0--66          8             41                58                                                                
  During/after RT     16                 0--100         16            41                50                                                                
  In use              8                  0--75          2             12                60                                                                
  Total               110                0--100         16            4                 66                                                                
  Eating duration     No                 77             0--100        25                50                81                                              \< 0.001[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  0--50          0             25                37                                                                
  During/after RT     16                 0--100         25            25                25                                                                
                      In use             8              0--50         0                 0                 18                                              
                      Total              110            0--100        25                25                75                                              
  Symptom frequency   No                 77             7.10--100     52                66                85                                              
  During RT           9                  25--66         25            46                53                \< 0.001[a](#FN0170or-7){ref-type="table-fn"}   
  During/after RT     16                 26.70--83.90   38            56                69                                                                
                      In use             8              3.50--71.40   10                22                46                                              
                      Total              110            3.50--100     44                60                82                                              
  Food selection      No                 77             0--100        25                75                100                                             \< 0.001[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  0--100         25            25                75                                                                
  During/after RT     16                 25--100        25            37                75                                                                
                      In use             8              0--50         0                 0                 43                                              
                      Total              110            0--100        25                75                100                                             
  Communication       No                 77             0--100        50                75                100                                             0.031[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  0--100         0             50                100                                                               
  During/after RT     16                 0--100         6             62                100                                                               
                      In use             8              0--100        0                 18                50                                              
                      Total              110            0--100        25                75                100                                             
  Fear                No                 77             12.50--100    56                81                100                                             0.001[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  18.70--93.70   25            25                81                                                                
  During/after RT     16                 25--100        32            50                85                                                                
                      In use             8              6.20--93.70   12                25                65                                              
                      Total              110            6.20--100     37                75                93                                              
  Mental health       No                 77             0--100        40                80                100                                             \< 0.001[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  0--75          5             25                60                                                                
  During/after RT     16                 0--100         16            37                73                                                                
                      In use             8              0--50         0                 7                 23                                              
                      Total              110            0--100        20                60                100                                             
  Social              No                 77             0--100        57                85                100                                             \< 0.001[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  35--75         35            40                72                                                                
  During/after RT     16                 0--100         25            47                82                                                                
                      In use             8              0--35         0                 12                25                                              
                      Total              110            0--100        38                75                100                                             
  Sleep               No                 77             0--100        68                100               100                                             0.458
  During RT           9                  25--100        50            87                100                                                               
  During/after RT     16                 25--100        50            93                100                                                               
  In use              8                  12.50--100     50            75                100                                                               
  Total               110                0--100         50            100               100                                                               
  Fatigue             No                 77             0--100        62                83                100                                             0.001[a](#FN0170or-7){ref-type="table-fn"}
  During RT           9                  0--100         25            50                66                                                                
  During/after RT     16                 0--100         33            75                100                                                               
                      In use             8              0--83.30      8                 25                62                                              
                      Total              110            0--100        41                75                100                                             

Abbreviations: max., maximum; min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: *p* value according to Kruskal-Wallis test.

*p* \< 0.05.

###### Association between SWAL-QOL and the presence of nasogastric tube

  Variable            Not during radiotherapy   Not during/after radiotherapy   Not in use    During radiotherapy or during/after radiotherapy   During radiotherapy or in use   During/after radiotherapy or in use
  ------------------- ------------------------- ------------------------------- ------------- -------------------------------------------------- ------------------------------- -------------------------------------
  Burden              0.156                     0.237                           0.011         0.626                                              0.372                           0.036
  Eating duration     0.015                     0.061                           \< 0.001^a^   0.305                                              0.138                           0.006^a^
  Symptom frequency   0.003^a^                  0.030                           \< 0.001^a^   0.084                                              0.092                           0.009
  Food selection      0.021                     0.046                           \< 0.001^a^   0.373                                              0.070                           0.006^a^
  Communication       0.139                     0.253                           0.007         0.638                                              0.455                           0.166
  Fear                0.013                     0.139                           0.002         0.228                                              0.324                           0.059
  Mental health       0.005^a^                  0.020                           \< 0.001^a^   0.392                                              0.155                           0.016
  Social              0.004^a^                  0.009                           \< 0.001^a^   0.886                                              0.001^a^                        0.011
  Fatigue             0.008^a^                  0.317                           0.001^a^      0.144                                              0.241                           0.024

Abbreviations: max., maximum; min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: *p* value according to Bonferroni correction (*p* = 0.008512).

The questionnaire also identified a statistically significant impact of the definitive tracheotomy in the communication domain (*p* \< 0.001; [Tables 6](#TB0170or-6){ref-type="table"} and [7](#TB0170or-7){ref-type="table"}).

###### Association between SWAL-QOL and the presence of tracheotomy

  Variable              Tracheotomy        *n*           min.--max.    25th percentile   50th percentile   75th percentile                               *p*
  --------------------- ------------------ ------------- ------------- ----------------- ----------------- --------------------------------------------- ------------------------------------------------
  Burden                No                 85            0--100        25                50                100                                           0.042[a](#FN0170or-12){ref-type="table-fn"}
  Definitive            8                  0--100        0             6                 43                                                              
  Temporary during RT   13                 12.50--100    25            37                50                                                              
                        Temporary use      4             0--87.50      6                 50                84                                            
                        Total              110           0--100        25                50                100                                           
  Desire                No                 85            0--100        20                41                70                                            0.133
  Definitive            8                  0--50         8             16                43                                                              
  Temporary during RT   13                 0--100        12            41                75                                                              
  Temporary use         4                  0--83.30      2             24                72                                                              
  Total                 110                0--100        16            41                66                                                              
  Eating duration       No                 85            0--100        25                25                75                                            0.153
  Definitive            8                  0--75         6             25                43                                                              
  Temporary during RT   13                 0--100        25            25                37                                                              
                        Temporary use      4             0--100        0                 12                81                                            
                        Total              110           0--100        25                25                75                                            
  Symptom frequency     No                 85            7.10--100     48                60                85                                            
  Definitive            8                  3.50--91      24            44                63                0.042[a](#FN0170or-12){ref-type="table-fn"}   
  Temporary during RT   13                 26.70--75     39            50                60                                                              
                        Temporary use      4             8.90--78.50   12                46                75                                            
                        Total              110           3.50--100     44                60                82                                            
  Food selection        No                 85            0--100        25                75                100                                           0.019[a](#FN0170or-12){ref-type="table-fn"}
  Definitive            8                  0--75         25            25                25                                                              
  Temporary during RT   13                 0--100        25            50                87                                                              
                        In temporary use   4             0--75         12                56                71                                            
                        Total              110           0--100        25                75                100                                           
  Communication         No                 85            0--100        50                100               100                                           \< 0.001[a](#FN0170or-12){ref-type="table-fn"}
  Definitive            8                  0--100        6             50                50                                                              
  Temporary during RT   13                 0--100        0             25                62                                                              
                        Temporary use      4             0--25         0                 0                 18                                            
                        Total              110           0--100        25                75                100                                           
  Fear                  No                 85            12.50--100    46                81                100                                           0.022[a](#FN0170or-12){ref-type="table-fn"}
  Definitive            8                  6.20--93.70   25            31                57                                                              
  Temporary during RT   13                 25--100       28            37                87                                                              
                        Temporary use      4             25--100       25                46                92                                            
                        Total              110           6.20--100     37                75                93                                            
  Mental health         No                 85            0--100        25                70                100                                           0.054
  Definitive            8                  5--100        6             15                25                                                              
  Temporary during RT   13                 10--100       20            45                75                                                              
                        Temporary use      4             0--100        0                 35                92                                            
                        Total              110           0--100        20                60                100                                           
  Social                No                 85            0--100        40                75                100                                           0.003[a](#FN0170or-12){ref-type="table-fn"}
  Definitive            8                  15--75        22            32                53                                                              
  Temporary during RT   13                 0--100        15            40                87                                                              
                        Temporary use      4             0--85         17                72                82                                            
                        Total              110           0--100        38                75                100                                           
  Sleep                 No                 85            0--100        50                100               100                                           0.207
  Definitive            8                  50--100       50            62                8                                                               
  Temporary during RT   13                 25--100       68            100               100                                                             
  Temporary use         4                  12.50--100    21            75                100                                                             
  Total                 110                0--100        50            100               100                                                             
  Fatigue               No                 85            0--100        58                75                100                                           0.199
  Definitive            8                  25--100       25            37                75                                                              
  Temporary during RT   13                 0--100        29            83                100                                                             
                        Temporary use      4             0--100        0                 37                93                                            
                        Total              110           0--100        41                75                100                                           

Abbreviations: max., maximum; Min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders (SWAL-QOL) questionnaire.

Note: *p* value according to Kruskal-Wallis test.

*p* \< 0.05.

###### Association between SWAL-QOL and the permanence of tracheotomy

  Variable            Not definitively                              Not temporarily during RT                     Not in temporary use                          Definitively or temporarily during RT   Definitively in temporary use   Temporarily during RT in temporary use
  ------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------- ------------------------------- ----------------------------------------
  Burden              0.115                                         0.116                                         0.0525                                        0.051                                   0.332                           0.908
  Symptom frequency   0.068                                         0.032                                         0.0212                                        0.514                                   0.865                           0.821
  Food selection      0.005[a](#FN0170or-15){ref-type="table-fn"}   0.0190                                        0.199                                         0.091                                   0.275                           0.773
  Communication       0.019                                         0.002[a](#FN0170or-15){ref-type="table-fn"}   0.002[a](#FN0170or-15){ref-type="table-fn"}   0.628                                   0.059                           0.110
  Fear                0.009                                         0.068                                         0.346                                         0.239                                   0.481                           0.818
  Social              0.002[a](#FN0170or-15){ref-type="table-fn"}   0.022                                         0.308                                         0.636                                   0.267                           0.690

Abbreviations: max., maximum; Min., minimum; RT, radiotherapy; SWAL-QOL, Quality of Life in Swallowing Disorders questionnaire.

Note: *p* value according to Mann-Whitney test adjusted by Bonferroni correction.

*p* = 0.008512.

Alcohol consumption had a negative influence on QOL in the domains of communication (*p* = 0.020) and mental health (*p* = 0.031). The burden (25 × 9.38), social (40 × 33.75), and fatigue (52 × 33.3) domains were identified via differences in scores as well. On the other hand, patients who continued to smoke presented worse results on the burden (*p* = 0.003), mental health (*p* = 0.030), and fatigue (*p* = 0.028) domains.

Discussion
==========

The incidence of posttreatment dysphagia in patients with head and neck cancer has previously been reported to be between 50 and 60%.[@JR0170or-13] [@JR0170or-14] Furthermore, it has been estimated that 30 to 50% of patients with head and neck cancer demonstrate some degree of malnutrition.[@JR0170or-5] The combination of dysphagia with poor nutrition, significant weight loss, and impaired immune function often results in cachexia, fatigue, high susceptibility to infection, poor wound healing, or death.[@JR0170or-5] [@JR0170or-15]

The most common acute side effects of chemoradiotherapy are mucositis, pain, dermatitis, xerostomia, loss of taste, hoarseness, weight loss, myelosuppression, nausea, and dysphagia. The most frequent late side effects are xerostomia, loss of taste, fibrosis, trismus, and dysphagia. Dysphagia has a potential for aspiration and death due to aspiration pneumonia.[@JR0170or-5] [@JR0170or-16] Thus, it is important to evaluate the short-, medium-, and long-term functional outcomes of radiotherapy treatment associated or not with chemotherapy. Some factors related to pretreatment status, such as weight, staging, primary tumor site, and treatment modality, interfere in the outcome and the QOL.[@JR0170or-17] [@JR0170or-18] [@JR0170or-19]

We found the median scores of SWAL-QOL for the whole group showed some loss in almost all domains, even 6 to 12 months following treatment completion. Some aspects specifically related to feeding, such as desire, eating duration, burden, food selection, and fear, seemed to have relevance for those patients, jeopardizing their mental health. A person with dysphagia spends a longer time eating, presents lower skill to eat varied food, and can be afraid, constrained, and/or incapable of eating in public, remaining socially isolated and depressed.[@JR0170or-14]

Men are more prone to be affected than women, showing a greater difficulty to adapt.

Dysphagia is common after the treatment of head and neck cancer; mucositis, nausea, loss of eating desire, taste changing, and xerostomia can make eating difficult and cause fatigue, jeopardizing the QOL.[@JR0170or-20] The fatigue domain presented a higher impact among patients with oral cancer. In fact, eating for a longer time can cause a feeling of fatigue. On the other hand, laryngeal cancer showed an impact on communication, due to mucosa dryness, fibrosis, muscular atrophy, and edema, which are consequent to radiotherapy and can affect vocal production.[@JR0170or-21] [@JR0170or-22] [@JR0170or-23] In addition, tumor location itself has some importance.

Patients with advanced primary tumor presented worse results. In contrast, the stratification of the patients according to the cervical staging (N) had no relationship with the QOL in our study, but other studies found that bilateral neck irradiation contributes to worse functional outcome.[@JR0170or-18]

Most of our patients (74.5%) underwent concomitant chemoradiotherapy with greater harm on the burden domain. The effects of late radiation-induced toxicity on deglutition and the salivary glands are more intense in the first 12 months after treatment and decrease gradually after 18 to 24 months.[@JR0170or-24] It should also be mentioned that dysphagia and QOL are damaged in advanced tumors, worsen during chemoradiotherapy, and improve 6 months after the treatment.[@JR0170or-25] We studied patients whose period after the treatment conclusion varied from 6 to 12 months. When the SWAL-QOL was associated with the type of treatment, the first aspect accentuated was the domain of burden (which is related to dysphagia), followed by the domains of fatigue (related to feeding deficit) and communication (related to the tumor and treatment sequel).

The use of a nasogastric tube had an important impact on all domains of the questionnaire, worsening the QOL. A nasogastric tube changes the daily routine and needs special care. Furthermore, feeding time is longer than habitual, and as a result there are social isolation and mental health aspects to its use. The weight loss during and in the 3 months after radiotherapy is independently associated with the QOL in patients with head and neck cancer.[@JR0170or-26] The use of tracheotomy also affects the QOL, according to the questionnaire, mainly with regard to communication, mental health, and social life. These three domains are clearly related to each other in patients with tracheotomy. The communication domain showed a higher impact during temporary use and during the radiotherapy performance, whereas the social function and food selection domains more often identified definitive use. Food selection harm can be a consequence of posttreatment edema, which damages the pharyngeal transit and might require dietary adaptation to minimize the treatment sequela.[@JR0170or-23]

Mental health was jeopardized among patients who continued to consume tobacco and alcohol. Such patients are prone to depression. The maintenance of those habits is responsible for a lower QOL.[@JR0170or-17] [@JR0170or-18] [@JR0170or-27] [@JR0170or-28]

Dysphagia is generally underdiagnosed or is not properly considered. Despite not replacing the clinical and instrumental evaluations, QOL questionnaires can contribute to evaluating specific aspects regarding the patient\'s well-being and can point out some characteristics that are not measured by pathophysiological parameters.[@JR0170or-29] [@JR0170or-30]

Conclusion
==========

The effects of radiotherapy and chemoradiotherapy on swallowing function are relevant on dysphagia-related QOL. The harm caused by dysphagia from 6 to 12 months after treatment is recognized by patients with advanced tumors. The type of treatment (concomitant combined radiotherapy and chemotherapy), use of nasogastric tube, tracheotomy, and continuation of tobacco and alcohol habits contribute to decreased QOL. The SWAL-QOL questionnaire is a useful and sensible tool to detect difficulties and perspectives of patients with head and neck cancer.
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